Abstract
Introduction Nearly 50% of patients with metastatic melanoma harbor a BRAFV600-mutation, which can be targeted with the use of BRAF and MEK inhibitors......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
